Monique Dontenwill

List of Publications by Year
in descending order

69	2,513	186265	206112
papers	citations	28 h-index	48 g-index

69	69	69	2976
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of Î±5Î²1 Integrin. Cancers, 2022, 14, 369.	3.7	2
2	Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas. Cancers, 2022, 14, 1482.	3.7	5
3	Biological Relevance of RGDâ€Integrin Subtypeâ€Specific Ligands in Cancer. ChemBioChem, 2021, 22, 1151-1160.	2.6	30
4	Gefitinib induces EGFR and Î±5Î²1 integrin co-endocytosis in glioblastoma cells. Cellular and Molecular Life Sciences, 2021, 78, 2949-2962.	5.4	16
5	A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers, 2021, 13, 1795.	3.7	67
6	A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value. Cancers, 2021, 13, 2252.	3.7	2
7	Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 3038.	3.7	7
8	Expression Analysis of Î±5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma. Pharmaceuticals, 2021, 14, 882.	3.8	3
9	Advanced quantification for single-cell adhesion by variable-angle TIRF nanoscopy. Biophysical Reports, 2021, 1, 100021.	1.2	5
10	Hypoxia Inducible Factorsâ€™ Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches. Cancers, 2020, 12, 979.	3.7	15
11	RNA Aptamers Targeting Integrin Î±5Î²1 as Probes for Cyto- and Histofluorescence in Glioblastoma. Molecular Therapy - Nucleic Acids, 2019, 17, 63-77.	5.1	26
12	Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer. Cancers, 2019, 11, 692.	3.7	47
13	Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity. Cancers, 2019, 11, 1875.	3.7	14
14	TGFÎ², Fibronectin and Integrin Î±5Î²1 Promote Invasion in Basal Cell Carcinoma. Journal of Investigative Dermatology, 2018, 138, 2432-2442.	0.7	29
15	Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers. Cancers, 2017, 9, 69.	3.7	80
16	Glioma cell dispersion is driven by Î±5 integrin-mediated cellâ€“matrix and cellâ€“cell interactions. Cancer Letters, 2016, 376, 328-338.	7.2	34
17	Formation of multicellular tumor spheroids induced by cyclic RGD-peptides and use for anticancer drug testing in vitro. International Journal of Pharmaceutics, 2016, 506, 148-157.	5.2	45
18	Expression/activation of Î±5Î²1 integrin is linked to the Î²-catenin signaling pathway to drive migration in glioma cells. Oncotarget, 2016, 7, 62194-62207.	1.8	36

#	Article	IF	Citations
19	Î²1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer. Frontiers in Pharmacology, 2015, 6, 279.	3.5	92
20	Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased epithelial to mesenchymal transition and prometastatic properties. Oncotarget, 2015, 6, 41884-41901.	1.8	30
21	Single cell tracking assay reveals an opposite effect of selective small non-peptidic Î±5Î²1 or Î±vÎ²3/Î²5 integrin antagonists in U87MG glioma cells. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 2978-2987.	2.4	21
22	Quantitative measurement of delivery and gene silencing activities of siRNA polyplexes containing pyridylthiourea-grafted polyethylenimines. Journal of Controlled Release, 2014, 182, 1-12.	9.9	22
23	Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target Î±5 integrin in colon cancer cells. Cancer Letters, 2013, 336, 307-318.	7.2	41
24	Integrin Î±5Î²1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers, 2013, 5, 27-47.	3.7	159
25	Integrins and p53 pathways in glioblastoma resistance to temozolomide. Frontiers in Oncology, 2012, 2, 157.	2.8	30
26	Integrin Î±5Î²1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma. Cancer Research, 2012, 72, 3463-3470.	0.9	102
27	Methylation of imidazoline related compounds leads to loss of Î±2-adrenoceptor affinity. Synthesis and biological evaluation of selective I1 imidazoline receptor ligands. Bioorganic and Medicinal Chemistry, 2012, 20, 4710-4715.	3.0	13
28	Involvement of the TGFÎ² pathway in the regulation of Î±₅Î²₁ integrins by caveolinâ€1 in human glioblastoma. International Journal of Cancer, 2012, 131, 601-611.	5.1	29
29	Pyridylthiourea-grafted polyethylenimine offers an effective assistance to siRNA-mediated gene silencing in vitro and in vivo. Journal of Controlled Release, 2012, 157, 418-426.	9.9	33
30	Î±5Î²1 integrin antagonists reduce chemotherapyâ€induced premature senescence and facilitate apoptosis in human glioblastoma cells. International Journal of Cancer, 2010, 127, 1240-1248.	5.1	65
31	Liquid ordered phase in cell membranes evidenced by a hydration-sensitive probe: Effects of cholesterol depletion and apoptosis. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 1436-1443.	2.6	75
32	Caveolin-1 regulates glioblastoma aggressiveness through the control of Î±5Î²1 integrin expression and modulates glioblastoma responsiveness to SJ749, an Î±5Î²1 integrin antagonist. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 354-367.	4.1	44
33	Synthetic Viruslike Particles for Targeted Gene Delivery to Î±vÎ²3 Integrin-Presenting Endothelial Cells. Molecular Pharmaceutics, 2009, 6, 1544-1552.	4.6	25
34	Detection of a hypersialylated Î²1 integrin endogenously expressed in the human astrocytoma cell line A172. International Journal of Oncology, 2008, , .	3.3	5
35	Detection of a hypersialylated beta1 integrin endogenously expressed in the human astrocytoma cell line A172. International Journal of Oncology, 2008, 32, 1021-31.	3.3	8
36	The Small Î±5Î²1 Integrin Antagonist, SJ749, Reduces Proliferation and Clonogenicity of Human Astrocytoma Cells. Cancer Research, 2006, 66, 6002-6007.	0.9	70

#	Article	IF	Citations
37	Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397. Journal of Cell Science, 2005, 118, 4415-4425.	2.0	227
38	I1 imidazoline receptor-mediated effects on apoptotic processes in PC12 cells. Cell Death and Differentiation, 2004, 11, 1049-1052.	11.2	17
39	Alpha2-Adrenergic Receptors in Intestinal Epithelial Cells: Mechanisms of Signaling, Role, and Regulation. Medicinal Chemistry Research, 2004, 13, 170-189.	2.4	2
40	IRAS Is an Anti-Apoptotic Protein. Annals of the New York Academy of Sciences, 2003, 1009, 400-412.	3.8	23
41	IRAS, the human homologue of Nischarin, prolongs survival of transfected PC12 cells. Cell Death and Differentiation, 2003, 10, 933-935.	11.2	27
42	Imidazoline Binding Sites (IBS) Profile Modulation:Â Key Role of the Bridge in Determining I1-IBS or I2-IBS Selectivity within a Series of 2-Phenoxymethylimidazoline Analogues. Journal of Medicinal Chemistry, 2003, 46, 2169-2176.	6.4	26
43	[125I]2-(2-Chloro-4-iodo-phenylamino)-5-methyl-pyrroline (LNP 911), a High-Affinity Radioligand Selective for I1Imidazoline Receptors. Molecular Pharmacology, 2002, 62, 181-191.	2.3	17
44	Î±2-Adrenoreceptors Profile Modulation and High Antinociceptive Activity of (S)-(â^')-2-[1-(Biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole. Journal of Medicinal Chemistry, 2002, 45, 32-40.	6.4	30
45	Differential sensitivity to inverse agonists of GABAA/benzodiazepine receptors in rats with genetic absence-epilepsy. Epilepsy Research, 2001, 47, 43-53.	1.6	11
46	Respective contributions of Î±-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs. British Journal of Pharmacology, 2001, 133, 261-266.	5.4	36
47	Imidazoline Receptors in Cardiovascular and Metabolic Diseases. Journal of Cardiovascular Pharmacology, 2000, 35, S21-S25.	1.9	21
48	2-(2-Phenylcyclopropyl)imidazolines:â€‰ Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors. Journal of Medicinal Chemistry, 1999, 42, 2737-2740.	6.4	10
49	Does a second generation of centrally acting antihypertensive drugs really exist?. Journal of the Autonomic Nervous System, 1998, 72, 94-97.	1.9	15
50	Characterization of a partial cDNA clone detected by imidazoline receptor-selective antisera. Journal of the Autonomic Nervous System, 1998, 72, 98-110.	1.9	36
51	Co-detection by two imidazoline receptor protein antisera of a novel 85 kilodalton protein. Biochemical Pharmacology, 1998, 55, 649-655.	4.4	29
52	Evidence for the Existence of Imidazolineâ€Specific Binding Sites in Synaptosomal Plasma Membranes of the Bovine Brainstem. Journal of Neurochemistry, 1998, 71, 2193-2202.	3.9	28
53	Binding of new cirazoline derivative to imidazoline receptors from human brain. Neurochemistry International, 1997, 30, 9-16.	3.8	1
54	Further biochemical characterization of imidazoline binding sites from the human brainstem. Fundamental and Clinical Pharmacology, 1997, 11, 63-67.	1.9	2

#	Article	IF	Citations
55	Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity. Bioorganic and Medicinal Chemistry, 1997, 5, 833-841.	3.0	55
56	Polyclonal anti-idiotypic antibodies to idazoxan and their interaction with human brain imidazoline binding sites. European Journal of Pharmacology, 1996, 306, 211-218.	3.5	13
57	Antiidiotypic Antibodies as Tools to Study Imidazoline Receptors. Annals of the New York Academy of Sciences, 1995, 763, 140-148.	3.8	13
58	Imidazoline Receptors and Cardiovascular Regulations.. Annals of the New York Academy of Sciences, 1995, 763, 526-530.	3.8	9
59	Human brain imidazoline receptors: further characterization with [3H]clonidine. European Journal of Pharmacology, 1994, 266, 25-33.	2.6	81
60	Isolation of a human cerebral imidazoline-specific binding protein. European Journal of Pharmacology, 1994, 265, R1-R2.	3.5	26
61	Heterogeneity of imidazoline binding sites revealed by a cirazoline derivative. European Journal of Pharmacology, 1994, 271, 533-536.	3.5	8
62	Characterization of imidazoline binding protein(s) solubilized from human brainstem: Studies with [3H]idazoxan and [3H]clonidine. Neurochemistry International, 1994, 25, 183-191.	3.8	27
63	Polyclonal anti-idazoxan antibodies: characterization and purification. European Journal of Pharmacology, 1993, 246, 45-51.	2.6	7
64	New concepts on the central regulation of blood pressure. American Journal of Medicine, 1989, 87, S10-S13.	1.5	36
65	Rilmenidine selectivity for imidazoline receptors in human brain. European Journal of Pharmacology, 1989, 163, 373-377.	3.5	101
66	The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. European Journal of Pharmacology, 1989, 162, 1-9.	3.5	160
67	Evidence for the existence of a homogenous population of imidazoline receptors in the human brainstem. European Journal of Pharmacology, 1988, 150, 401-402.	3.5	59
68	Production and characterization of anti-clonidine antibodies not cross-reacting with catecholamines. European Journal of Pharmacology, 1988, 149, 249-255.	3.5	20
69	A polyclonal antibody raised against clonidine: a model for the specific imidazoline receptor. European Journal of Pharmacology, 1987, 137, 143-144.	3.5	13